Continue teclistamab for a limited time in responding patients
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This Phase 2 trial looks at stopping or limiting teclistamab after you’ve already had a good ongoing response. It aims to see if people can safely continue to benefit while using the medicine for a shorter time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be at least 18 years old and able to sign consent forms
- You started teclistamab (first full dose) about 6 to 9 months ago, and you’ve been receiving enough dose regularly since then
- You had a teclistamab dose within the last 4 weeks
- You had measurable disease when teclistamab started, and you achieved a very good response (VGPR or better) that is still ongoing (no progression)
- Before starting teclistamab, you previously received all of these: a proteasome inhibitor, a lenalidomide/pomalidomide-type medicine, and an anti-CD38 antibody; and either you had 3+ prior treatment lines or you were not responding to both a proteasome inhibitor and a thalidomide-type medicine
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests how well teclistamab works for people with multiple myeloma that has come back or not responded to at least three prior treatments. You may be eligible if you are starting teclistamab as part of your regular care.
This trial tests a combination of teclistamab (an immunotherapy) and your own immune cells to treat multiple myeloma that has come back or stopped responding to prior treatments. It is for people who have had 1 or 2 prior lines of therapy and have not received a BCMA-targeted treatment before.
This Phase 2 trial studies how well teclistamab works when used in combination for people age 65 and older with multiple myeloma. It aims to see whether this treatment can control the cancer safely in older patients who may not do high-dose chemotherapy or stem cell transplant.
This trial tests whether adding teclistamab to lenalidomide (or using teclistamab alone) helps keep newly diagnosed multiple myeloma from coming back after an autologous stem cell transplant. It’s comparing these options to lenalidomide alone as long-term maintenance.
This trial tests a lower dose of the drug teclistamab in people newly diagnosed with multiple myeloma. It aims to see if a lower dose is still effective and has fewer side effects.
This trial tests a combination of two drugs, teclistamab and pomalidomide, given in an alternating schedule to see if it helps people whose multiple myeloma has come back or stopped responding to previous treatments. The goal is to improve outcomes with manageable side effects.
Hear when a new Myeloma Multiple trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.